Group & # 39; by researchers Massachusetts Institute of Technology (MIT) developed a new experimental approach that allows medicine to combat artrosi by accessing the interior of the articular cartilage tirriġeneraha. This advance, tested in rats, is a step & # 39; ahead to achieve treatment slows the progression of & # 39; incurable diseases to this day.
The artrosi is a progressive degeneration of the cartilage of joints produced by aging or injury. This disease affects about 300 million people worldwide, and m & # 39; has no reverse, because cartilage is a tissue that can not regenerate. Though there are therapies that can reduce the symptoms of & # 39; osteoarthritis, s & # 39; m now & # 39; there is no treatment that can & # 39; reduce its progression.
One of the difficulties for treatment is that drugs can not easily enter the cartilage. Most of them removed from the joints before they enter into force or do not fit in the interior of cartilage, which is produced cells that are found, the chondrocytes, so can not perform their functions.
Thus, the researchers devised a nanocarrier, a molecule that acts as a vehicle that can & # 39; introducing cartilage and chondrocytes carrying medicine. The molecule consists & # 39; spherical part with binding drug, structures such as branches b & # 39; and positive electrical charge compound called PEG.
Since cartilage has a negative weight, the positive charges on nantransporter cause to adhere to the tissue. The PEG, on the other hand, allow open passage from the cartilage and b & # 39; so, ċekondroċiti reach citizens.
According to the magazine Translational Medicine ScienceScientists put medicine called IGF-1 with the nanocarrier, which has the function to stimulate the production of cartilage and survival and growth of chondrocytes. To test this experiment, the nanocarrier was injected into joints & # 39; the knee & # 39; rats had osteoarthritis from injury.
This treatment reduced cartilage destruction, inflammation and the appearance & # 39; changes in bone. Similarly, a nanocarrier, the half-life of the drug in joints multiplied by & # 39; ten. In addition, it was maintained at & # 39; effective concentrations cartilage for thirty days, thus potentially injection & # 39; every two weeks or every month is enough.
"It's a very interesting study", says Josep Verges, a physician and president of the International Foundation Osteoarthritis (OAFI), who was not involved in the research.
According Verges, if people had applied and been so effective in rats, can & # 39; improve the quality of life of patients, because it is sufficient b & # 39; one or two monthly injection. However, still needed to see whether confirmed in clinical trials. He adds that you & # 39; & # 39 takes between four; and eight years for this drug to be commercially available.